The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). It is approved in combination with platinum-based chemotherapy for patients with la/mNSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. Efficacy was evaluated in the Phase […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!